<DOC>
	<DOCNO>NCT01714739</DOCNO>
	<brief_summary>To assess safety tolerability preliminary anti-tumor activity lirilumab ( BMS-986015 ) give combination nivolumab ( BMS-936558 ) identify dose limit toxicity ( DLTs ) maximally tolerate dose ( MTD ) combination . In addition , assess combination lirilumab nivolumab lirilumab nivolumab plus ipilimumab ( BMS-734016 ) subject advance ( metastatic and/or unresectable ) refractory solid tumor .</brief_summary>
	<brief_title>A Study Anti-KIR Antibody Lirilumab Combination With Anti-PD1 Antibody Nivolumab Nivolumab Plus Anti-CTLA-4 Ipilimumab Antibody Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . During dose escalation , subject advance solid tumor ( except primary CNS metastasis ) progress follow least one standard regimen During cohort expansion , subject various solid tumor receive least one 5 prior treatment regimens Subjects must measurable disease Subject must consent provide previously collect tumor tissue Women men â‰¥18 year age performance status 0 1 At least 4 week since previous treatment cancer Active chronic autoimmune disease Uncontrolled significant cardiovascular disease Chronic hepatitis ( except subject hepatocellular carcinoma ) Active infection Active Central nervous system ( CNS ) metastases Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome ( ( HIV/AIDS ) Positive test Hepatitis B virus surface antigen Hepatitis C antibody ( except subject hepatocellular carcinoma ) Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>